http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0996458-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c0982b0f02b1ed6d20a315370a3a3a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 |
| filingDate | 1998-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbd7c5642c47bff82bff2e229466d394 |
| publicationDate | 2000-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0996458-A1 |
| titleOfInvention | Sandramycin analogs |
| abstract | Analogs of sandramycin (1) are synthesized and shown to have cytoxic activity against various tumor cell types. The relative cytotoxic properties of the sandramycin analogs are approximately parallel to their relative DNA binding affinities. An exception to this generalization is compound (4) which completely lacks the sandramycin chromophore phenol. Although typically 4-10x less potent than sandramycin against leukemia cell lines, compound (4) proved to be 1-10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting IC50 values of 1 pM-10 nM. This activity places compound (4) among the most potent agents identified to date. |
| priorityDate | 1997-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 422.